Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corvus Pharmaceuticals Inc CRVS

Healthcare Biotechnology
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in... see more

Recent & Breaking News (NDAQ:CRVS)

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 5, 2022

Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

GlobeNewswire April 26, 2022

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 10, 2022

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

GlobeNewswire March 3, 2022

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

GlobeNewswire January 13, 2022

New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

GlobeNewswire December 13, 2021

Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 12, 2021

Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 10, 2021

Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 2, 2021

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire November 1, 2021

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

GlobeNewswire October 27, 2021

Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818

PR Newswire October 25, 2021

Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease

GlobeNewswire September 22, 2021

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

GlobeNewswire September 7, 2021

Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China

GlobeNewswire August 16, 2021

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

GlobeNewswire August 2, 2021

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

GlobeNewswire July 15, 2021

Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 25, 2021

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

GlobeNewswire May 5, 2021

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

GlobeNewswire April 29, 2021